Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Veterans~* age 18 and above~* diagnosis of asthma and COPD per guidelines~* for asthma, persistent symptoms per guidelines~* for asthma, a pre-bronchodilator FEV1 55-90% and DLCO 80% predicted~* for asthma, physiologic confirmation by bronchodilator or methacholine challenge~* for COPD, a post-bronchodilator ratio of FEV1/FVC 70% and FEV1 50%~* overall smoking history of \<10 pack-years for asthma and 10 pack-years for COPD.~Exclusion Criteria:~* any use of inhaled corticosteroid for \>2 weeks at a time during the last 6 months, or any use in the last 6 weeks;~* as needed use of nasal steroids in the prior 6 months~* select medications~* recent exacerbation requiring oral or systemic steroids in the past 6 months~* diagnosed vocal cords dysfunction~* other lung diseases (lung cancer, sarcoidosis, tuberculosis, lung fibrosis) or known 1-antitrypsin deficiency~* significant or actively unstable medical or psychiatric illnesses~* diagnosed osteopenia or osteoporosis~* established diagnosis of neuromuscular disease~* BMI 45 kg/m2 and higher~* treated OSA~* pregnancy (confirmed on urine test) or desire to get pregnant in the upcoming 6 months.~* smoking in the past 6 months~* metallic or electronic implants~* claustrophobia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): High dose inhaled fluticasone (1760mcg/day)
- Arm 2 (Type: ACTIVE_COMPARATOR): Low dose inhaled fluticasone (88mcg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).